Elekta AB (EKTAY) Lowered to Neutral at J P Morgan Chase & Co
Elekta AB (OTCMKTS:EKTAY) was downgraded by J P Morgan Chase & Co from an “overweight” rating to a “neutral” rating in a research report issued on Monday, November 13th, Marketbeat.com reports.
Separately, Zacks Investment Research downgraded Elekta from a “buy” rating to a “hold” rating in a report on Friday, October 27th.
Elekta (OTCMKTS EKTAY) traded down $0.05 on Monday, reaching $8.69. The company’s stock had a trading volume of 42,893 shares, compared to its average volume of 43,063. The company has a market cap of $3,203.03, a price-to-earnings ratio of 173.80, a price-to-earnings-growth ratio of 1.35 and a beta of 0.54. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.30 and a quick ratio of 1.16. Elekta has a fifty-two week low of $7.97 and a fifty-two week high of $11.18.
ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/11/26/elekta-ab-ektay-lowered-to-neutral-at-j-p-morgan-chase-co.html.
Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies.
Receive News & Ratings for Elekta AB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta AB and related companies with MarketBeat.com's FREE daily email newsletter.